Negative WPI Set To Trigger Price Cuts In India?
This article was originally published in PharmAsia News
The going has generally been tough for pharmaceutical firms in India this past year, stretched by volatility in certain emerging markets and plant woes, but the industry there should probably steel itself for yet more pain on its home turf.
You may also be interested in...
Fresh efforts to rein in drug prices may be on the cards in India, as the government evaluates linking prices of all medicines to a wholesale price index. Industry anticipates "major disruption" if the proposal goes through.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.